Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name MGD013
Synonyms
Therapy Description

MGD013 is an engineered antibody protein that targets both PDCD1 (PD-1) and LAG3 resulting in enhanced T-cell mediated anti-tumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MGD013 MGD-013 Immune Checkpoint Inhibitor 94 LAG3 Antibody 10 PD-L1/PD-1 antibody 63 MGD013 is an engineered antibody protein that targets both PDCD1 (PD-1) and LAG3 resulting in enhanced T-cell mediated anti-tumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable MGD013 Phase I Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in 7.3% (3/41) and stable disease in 51.2% (21/41) of response-evaluable patients with advanced solid tumors in the dose escalation cohort (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown ovary epithelial cancer not applicable MGD013 Phase I Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in 13.3% and stable disease in 46.7% (7/15) of patients with epithelial ovarian cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown stomach cancer not applicable MGD013 Case Reports/Case Series Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in a patient with gastric cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown malignant mesothelioma not applicable MGD013 Case Reports/Case Series Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in a patient with mesothelioma (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown triple-receptor negative breast cancer not applicable MGD013 Phase I Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in 14.3% (2/14) and stable disease in 35.7% (5/14) of patients with triple-receptor negative breast cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT03219268 Phase I MGD013 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Recruiting


Additional content available in CKB BOOST